Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unknown
Excellent questions BeerlsGood. This is what we know. During the IFAH interview (admittedly, not the best interview and it was done by a young individual who did not appear very knowledgeable at all). Doctor Dalton commented about Opioid Dependence and then stated that "we are the solution." Dalton also stated that he had been working with John's Hopkins for years with their treatment program. I suspect the "SOLUTION" Doctor Dalton commented on regarding Opioid Dependence is what Dalton won the award for, but that is only speculation based on his comments. This is the clearest indication we currently have. However, I state once again, IFAH only awards for actual accomplishments so he did something of world wide significance that he claimed involved the Univec Conglomerate. I was told that IFAH directly involved Univec by Doctor Dalton when he asked me to contact those hyping Hope Global Forum and get them to correct the record. Some comments were made at Hope Global that do reference Univec, but nothing to indicate the direction of the company.
These are powerful hints about what Dalton and Univec may be doing, but with the exception of tweets and LinkedIn posts, we have not been given a whole lot more.
Important background information some Univec shareholders may find helpful. I suggest doing your own due diligence and do not rely on others.
Currently, Israel can technically export cannabis, but only after meeting the domestic demand. The Ministry of Health from the State of Israel announced in November that it will allow the importation of cannabis to Israel, to ease the significant shortage that exists in the Israeli market. I suggest checking who is importing.
Compounding the quagmire of not having enough medical cannabis available domestically for patients, let alone for export abroad. The nation's largest producer was shut down by the government, further complicating matters.
The issue of sale and export of Israeli medical cannabis has frustrated local marijuana farmers, causing a harvest overflow. Subsequently, Israeli streets were overflowing with otherwise unsellable herb. (see Israel decriminalized adult-use cannabis possession in April, of 2019.)
Although there is a moratorium on exports, research and development (R&D) in Israel continues to flourish, and the country holds its position as an industry leader in cannabis science. Unsurprising, considering Israel has always led the way in cannabis R & D, beginning with Prof. Raphael Mechoulam and his partner Y. Gaoni’s discovery and isolation of the tetrahydrocannabinol (THC) molecules. Prof. Mechoulam is a pioneer in the field, whose significant work includes identifying the human body’s endocannabinoid system and another active ingredient of the plant, cannabidiol (CBD).
Israeli cannabis company Tikun Olam, for example, created a USA subsidiary and licensed its cultivation technology to iaso for cultivation in Puerto Rico.
Israeli company Kanabo has sold to England-based Spinnaker and is about to go public on the London Stock Exchange.
Laura Kam, President of Kam Global Strategies, a strategic communications company with many Israeli cannabis clients, summarizes the current situation in Israel.
“There has been significant investment in cannabis farms and technology in Israel over the past several years with the view to export; but due to bureaucratic infighting and now, with a caretaker government that is unable to give the final regulatory nod to export its crops as flower, oil or in other forms, there is much angst within the Israeli cannabis ecosystem. Many have decided to invest their funds and technological know-how outside of the country, setting up farms in places like Malta and Uganda and investing in or founding cannabis companies around the world, from Poland to the United States to Australia and elsewhere.”
It appears to be a shame that a country at the forefront of cannabis technology, research and innovation, is still unable to export domestically cultivated cannabis.
Even if the government officially lifted the moratorium on Israeli cannabis cultivation for export, not all Israeli cannabis companies are currently compliant under the complicated Good Manufacturing Practices certified for Europe (Eu-GMP). Therefore, once export is genuinely approved in praxis, it still must meet the additional logistical hurdles and stringent criteria for importation to Europe.
https://www.forbes.com/sites/sarabrittanysomerset/2019/12/07/israel-rescinds-moratorium-on-cannabis-exportation-now-what/#51f78dbe4594
While Israel is world-renowned for pioneering cannabis cultivation and its extraction technologies, producers have been left frustrated in recent months as the government has repeatedly stalled on giving growers the green light to export.
However, a bill that was passed unanimously by the Knesset last month – providing for the export of medical cannabis and implementing regulations for the licensing of medical cannabis businesses – assured producers that the wait was nearly over.
Licenses will be exclusively granted by the Health Ministry and will require police approval.
“This is a dramatic step that was only approved after it passed all the necessary meticulous procedures by Israeli professionals, in full cooperation with the relevant government ministries.”
There are currently eight companies cultivating cannabis for medical purposes in Israel, and dozens more have applied for approval to commence work in the field.
Cann10 Chairman Yossi Bornstein said Israel’s success in approving exports does not end with the government’s decision. “The great test is the time that will pass between the decision to write the regulations and the actual production.” “We hope that, contrary to the nature of Israeli bureaucracy, this won’t be a long process. Otherwise, the State of Israel will lose more precious time on its way to becoming an important player in the global industry.”
https://www.jpost.com/Israel-News/Israel-gives-green-light-to-medical-cannabis-exports-578815
Israeli cannabis companies can now export their products, but there is still a hook. Before international exports can be allowed, the local cannabis industry must first be able to satisfy the domestic demand for medical cannabis.
Unfortunately, there is a shortage of medical cannabis in Israel since one of the country’s largest growers, Tikun Olam, was temporarily closed due to concerns over the drying process.
https://hemp.im/israels-cannabis-industry-to-finally-export-cannabis/
The above information is important for Univec shareholders, but it is not the end of the story. Doctor Dalton said we would have control of our product from the beginning to the end of the supply chain. Our product will be controlled and in compliance from soil (or growing medium) to seed to processing to finished product. And, we will be designated the gold standard. According to Doctor Dalton, he has had clinical trials on-going since at least the days of AgriMed. This means these trials started before the passage of the 2018 farm bill, and that indicates that no U.S. companies were the source for Dalton’s clinical trials. We were also told the source of our cannabis would be international, and could supply all of our needs even if our products were distributed internationally. This indicates or at least suggests our source is an established company that does everything and has the necessary certifications to do so. I have no reason to disbelieve Doctor Dalton's claim of doing clinical trials. I say this because IFAH awarded Doctor Dalton one of the top 100 medical professional in the entire world, and that award is only given for something actually accomplished. Not for something one hopes to do, maybe, sometime in the future, if all goes well and the moon continues shining.
I can name three or maybe four companies that can actually meet all the requirements listed above. Perhaps others can find more, but there certainly are not very many. So, I suggest people do their own homework and ask some serious questions. From what I can see, this could all be good news for Univec.
Kgem
You are correct BeelsGood, the claim of "Gold Standard" is a designation that is awarded to companies in Israel and in Canada. However, no U.S. company has such an award that I am aware of. Although I do know of one Canadian company that is also incorporated in the U.S. that has both Canadian and Israeli gold standard designation.
No product has yet been "proven" to be clinically approved by Doctor Dalton. I do believe Doctor Dalton is attempting to get products tested and approved, but claiming something is "proven" is a false statement with no collaboration at all. I suggest asking for proof of such claims from anyone who posts otherwise. You will find that at this time there is none.
The following is the latest informative post from Doctor Eric I. Mitchell just out today. This information is important for Univec because it speaks to the research currently being conducted in Israel on products purported to be in the pipeline. While we have no definitive proof of any current marketable products (nothing is being sold), there is much talk that such products are being developed and will be marketed soon. I, like everyone else, can speculate on what soon really means because it has been a very long time since anything of any real value has been reported by Univec. Once again, this information is important, but speculative regarding Univec until we have firm confirmation. I do not intend to spin wild stories to entice people to buy or sell based on this or any other information.
CBDA Plus CBD = Better?
SURPRISE! SURPRISE!
The question first: What is Cannabidiolic Acid (CBDA) and what makes it different from CBD and why has it become so important and so very important when it comes to the Endocannabinoid System (ECS) and the healthcare world? Dr. Raphael Mechoulam, The Godfather of Cannabis, an Israeli organic chemist and Professor of Medicinal Chemistry at the Hebrew University of Jerusalem, remembers the letdown after his groundbreaking discoveries surrounding the structure of the cannabis compounds CBD and THC
in 1963 and 1964.
It would take Dr Mechoulam more than 30 years from the 1960s to the 1990s before his clinical work on using CBD as medicine would be understood via the ECS. It would take another 28 years after this same Professor at the same University explained the ECS before clinical applications would spring up like long sleeping bamboo sprouts to new heights and now patented medicines like Epidiolex in 2018.
The last two years of unbridled research has occurred since December 2018 when the Drug Enforcement Administration’s (DEA) oversite of cannabis with less then .3% THC by weight was lost by this agency.
Cannabis with less than 0.3% THC was now determined as hemp and not medical cannabis or Marijuana. This new-found freedom to study this plant has posed more questions than have been answered as American researchers get on board. These restrictions on cannabis research were lifted after the passage of the 2018 Farm Bill, where hemp was redefined as outlined above. We have often heard that the sum parts are greater than a whole. What does that really mean?
I believe it means that if you take the value of each individual piece of the pie, the value of the whole pie is much greater because of all of the positive elements of each piece of the pie. I believe this is a big part of the Cannabis story.
When it comes to the Cannabis sativa L plant, there are about 114 different Cannabinoids or pieces that make up this Cannabis pie. So, where do you start? As an operative Orthopaedic Surgeon for almost 40 years, I looked for the two largest pieces of a fractured bone and then found that third piece and started putting things back together. So, let’s GO!
There are three major acid forms that are created by the Cannabis sativa L plant from its precursor cell structure called CBGA (cannabigerolic acid). They are: THCA, CBDA, CBCA. These three acid forms each have a different degree of chemical stability.
THCA is heat sensitive when converted to THC which is the psychogenic form that makes you high. Cannabidiol (CBD) and Cannabidiolic Acid (CBDA) are both well-known as abundant chemical compounds native to the cannabis and hemp plant. The CBDA is heat and time sensitive and is the precursor to CBD which has received new meaning in the medical world for its treatment of many different human maladies. CBCA is the third most common acid form of Cannabinoids, and it, too, requires heat to thermal decarboxylation, away from a less stable chemical compound to a more stable chemical form. More on this CBCA later!
Cannabinoids are cannabis compounds that interact with our bodies to produce medical CBD, the major non-psychoactive cannabinoid in cannabis. CBD has been well investigated for its suspected therapeutic potential, and is currently thought to be able to treat epilepsy, inflammation, anxiety disorders, and a number of other common physical and neuropsychiatric conditions. These medical benefits are believed to be activated through the CB1 and CB2 receptors in our body located in the ECS.
First discovered in 1964 by Israeli researchers, Yechiel Gaoni and Raphael Mechoulam, CBG plays a significant role in the biology of cannabis plants. From there, plant enzymes unique to each cannabis strain convert the CBGA into some varying combinations of the three major cannabinoid precursor compounds: tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) and cannabidiolic acid (CBDA).
Once CBDA has been formed, it is then converted into CBD by thermal decarboxylation, whereby heat causes the molecule to lose its acidic carboxyl group. This decarboxylation process can either happen instantly, such as when the cannabis material is lit and smoked or vaporized, or by slow degradation over time if the plant material is left to sit at room temperature. Dr. Mechoulam, in a recent lecture in November 2019, stated that he has found a way to stabilize CBDA thereby making it a much more therapeutic modality. He stated that he hopes that researchers do not sit on this fact.
Normally, CBDA and the other acidic forms of cannabinoids are not considered to be pharmacologically active. This is because they do not work through the body’s ECS in the same way that their decarboxylated forms, CBD do. As a result, most research has focused on the effects of CBD and THC, rather than CBDA and THCA. Surprise, surprise, the acid form of CBD, CBDA uses a different pathway to reduce pain and inflammation.
CBDA is also thought to be a powerful treatment for nausea and anxiety. A 2013 study from scientists in Guelph, Canada, found that CBDA was a thousand times more powerful than CBD in binding to a specific serotonin receptor linked to anti-nausea and anti-anxiety effects. CBDA works through a different receptor system that is analogous to the Cox 1 and Cox 2 inhibitors of inflammation. So, therefore, CBDA and CBD working in a synergistic fashion may give us more effective medications using two courses of action for increased efficacy.
What does this mean for us? Some recent studies showing equal parts CBD and CBDA in combination may well be a new and welcome surprise for this age-old botanical—Surprise! Surprise! Surprise!
Please and thank you, Dr. Eric I.
Authored by:
Eric I. Mitchell, MD MA FACPE CPE
I am doing better BeerlsGood, and thank you.
Good Afternoon Univec Conglomerate Investors. I often post about the importance of high-grade processing and the state of the art in the cannabis industry, but there is one thing that fascinates me most, and it is the subject of CBD and nanotechnology.
The main reason being that I’ve learned so much more about the biological and chemical challenges of optimizing the bioavailability of cannabidiol (CBD). In other words, I’ve realized that the story isn’t about the efficacy and well-documented Cannabis science, it’s all about what CBD nanotechnology is bringing to Federal agencies and State and Local Taxing Authorities.
Trillions have been invested by big pharma in nano-science over the last three decades, but curiously little has been invested in delivery systems for drug medications --- until now. Hence, the interest in a CBD transdermal patch.
What is nanotechnology? Nanotechnology achieves the objective of manipulating atoms, molecules, and supramolecular formations and reducing their scale to between 1 and 100 nanometers (nm) according to the National Nanotechnology Initiative.
You can say that this means that our scientists are reducing particles and materials to one-millionth of their original size and even further.
Current examples of nanotechnology are now widespread including nano-medicine, biomaterials, microscopic devices, robots, computer chips, and essential organic compounds like CBD.
It wasn’t until the 80’s and the invention of scanning tunneling microscopes that we were able to actually see the nano-particles we were forming!
Today, scientists, physicians, and engineers are becoming very familiar with reducing the size of atoms, molecules… and yes, even physical devices to nanoscale. This is how they are realizing the enhanced properties of these particles and devices to achieve 100% bioavailability of organic phytonutrients like CBD compared to their original size counterparts.
No doubt about it. The primary trend in CBD manufacturing is nano-enhanced (nano-sized) cannabidiol (CBD). If you are a user of CBD hemp oil, you are probably well aware of this due to the number of new products increasing each month that “claim” to be incorporating nano-technology into their products and manufacturing.
The attractiveness and possibilities of nanotechnology and CBD began to take off after 2010. The reason for this is as follows:
• Creation of a 100% bioavailable delivery system for optimum effect
• Effective distribution throughout the body per dose
• Speed of delivery is significantly increased
* Better economies of scale in manufacturing – profit potential
Never before has nano-sized cannabidiol clusters been so stable in solution (water for example). And it is this development that has attracted the attention of the Federal Drug Administration (FDA) currently evaluating the efficacy of CBD nano-emulsification patented technologies.
In short, CBD nano-emulsified products will likely be the first FDA approved CBD products. And if that doesn’t excite you, then absolutely nothing will.
Creating pharmaceutical quality CBD products is about as high a bar a cannabis company can set for itself. And this is the clear objective with respect to a number of patents pending current review by the FDA. CBD companies and lab facilities are also applying for FDA Authorized Lab approvals and licenses which would be a CBD industry first.
Consumers expect product homogeneity, high quality, safety, and nano CBD products must be stabilized and duplicable. Otherwise, these products will not the meet strict homogeneity criteria required by the FDA and consumers alike.
Strict manufacturing standards and guidance for the human pharmaceutical industry is provided by the “Current Good Manufacturing Practice” regulations (CGMP). Further guidance for the industry includes “Packaging, Labeling, or Holding Operations for Dietary Supplements.”
Few people are aware of CGMPs, and how the FDA’s mandate to assure drug manufacturing standards, practices, and processes are changing the industry.
A word of caution. What I can discern from my own research is that the term “nano-enhanced hemp oil” can only be taken at face value. I find it difficult to find substantial proof online from most manufacturers. And from what I read in the highest ranked blog posts on the subject, I am amazed at the in-your-face inaccuracies and misinformation contained in them. I’ve found that most manufacturers are simply replicating well-established lyposomal, colloidal and/or micelle technologies and using standardized equipment. Nothing really new, and of course every company will argue that “theirs” is better than another due to their chemical and procedural approaches.
The problem with nano CBD product manufacturing is that CBD is very difficult to work with. Quite different than adding CBD isolate to oil, and then placing an attractive label on it. Many product websites make the most ignorant statements and claims from a biochemistry standpoint and thereby reveal their shortcomings and lack of scientific value. Thus, buyer beware.
Simply put, not all nano CBD products are created equal.
REFERENCES:
https://www.ncbi.nlm.nih.gov/pubmed/16304818
https://www.nano.gov/nanotech-101/what/definition
https://www.fda.gov/Drugs/DevelopmentApproval...169105.htm
http://blog.sonomechanics.com/blog/ultrasonic...nnabinoids
https://www.prnewswire.com/news-releases/cbd-...21169.html
http://eng.thesaurus.rusnano.com/wiki/article1199
https://www.genome.gov/27532724/epigenomics-fact-sheet/
https://becomingasuperhuman.com/nootropics-bi...en-fowkes/
Kgem
What is going on with EWKS this week? I don't see any news, but it appears something is waking this beast up. Anybody know anything?
While the following article was not written by Doctor Dalton, it certainly could have been. This writing outlines the road ahead for Univec Conglomerate, and for all of us.
Protection Against Chronic Diseases
We recently suggested that the practice of dietary approaches to the prevention of chronic diseases like cancer beget more frugal medicine and can serve rich and poor alike. Dietary delivery of protective phytochemicals makes good sense and chemoprevention by whole foods, or simple extracts of whole foods, presents unprecedented opportunities to solve unmet global problems. They are intuitively the most logical, sustainable, ethical, and responsible way to deal with the epidemic of chronic and degenerative disease. They may also be among the most cost-efficient, certainly compared to treatment of frank disease. This is a frugal and realistic strategy that is economically sustainable in the U.S. and in the underserved and economically deprived populations that are already moving toward more chronic illnesses.
A very straightforward starting point for this paradigm shift is for physicians to prescribe preventive diets for their at-risk patients. The food system in the U.S. can readily facilitate the delivery of such diets, but our medical and graduate schools must do a far better job of teaching new physicians and biomedical scientists about human nutrition and the role of diet in disease prevention, and those newly trained professionals must in turn be proactive with their patients and counselees. They must make prevention as much the order of the day as cure. Food—chemopreventive diets—should be, and can be, the daily “multivitamin” of our immediate future.
The challenge for the next decade(s) and for new health professionals is how to convey the learnings directly to their patients and to the general public. Social scientists, the entire spectrum of stakeholders in the food industry (e.g., from farmers to retailers), medical, nursing, and public health schools, government (e.g., regulatory and research branches), and primary and secondary school educators will all need to become invested and involved. The new drivers of this revolution will be not the drug companies but the food and agricultural interests because they will stand to profit greatly from introduction of new foods, new plant cultivars, and the reintroduction of “old foods” into new markets. They should thus be expected to provide a larger share of the funding for chemoprevention research as well as for effective public outreach. The road to longer healthspan will of course be rocky, but we cannot afford to ignore a strategy of diet-based prevention without putting our health care system in even more severe jeopardy than it already is.
Excerpted from: Fahey JW and TW Kensler (2013) American Medical Association Virtual Mentor 15(4): 311-318.
Good Morning All. Lots going on behind the scenes with Doctor Dalton and Univec Conglomerate. We are still in waiting mode, but progress is being made. Look for many changes going forward with emphasis on specific products to treat specific ailments. Look also for combinations of other plant molecules that may be added to CBD or even THC to treat and fight some of the biggest medical conditions of our time.
Chronic inflammation is a key prognostic marker of several life-threatening and disabling conditions, especially those associated with aging and obesity, and you typically do not know you have this ongoing chronic inflammation because your doctor may not even have looked for it.
Yes, obesity is considered a chronic inflammatory disease that will and can lead to the same endgame of acute inflammation that winds up being cellular tissue damage and death. Chronic inflammation can impact cardiovascular disease, heart failure, osteoporosis, some neurodegenerative conditions (including Alzheimer's disease), diabetes, and some cancers. Wow!!!!!!!!
We have a bodily system which Americans are just starting to learn about and pay attention to and it is called the Endocannabinoid System (ECS). This is a balancing and regulatory system within our bodies. We need to have external cannabinoids added to our diet when our bodies do not or cannot make enough. In the past, people typically got these phytocannabinoids from their foods, but our nutrient poor soil often no longer supplies these much-needed cannabinoids.
The renaissance of the plant Cannabis sativa L supplies many of these missing cannabinoids that help fight chronic inflammation in our bodies. As the public experiments and re-enters this market, beware of where you obtain your Full Spectrum Hemp Oil. Today, many companies are fractionating CBD oil and taking out the components like THC and stripping out the entourage effect and presenting the public with an isolate which is not the answer for the ECS and the fight against chronic inflammation.
This is the fight Doctor Dalton is engaged in. Doctor Dalton intends to change our world, and the way the medical profession studies and looks at ailments.
Kgem
Cannabis and CBD: Naturally effective treatment method for restless leg syndrome
Submitted by Marijuana News on Thu, 11/21/2019 - 11:16
Even though there’s currently no cure, there are natural treatment methods available like cannabis and cannabidiol that can help alleviate many RLS symptoms.
What would you do if you felt a consistent tingling, itching, and/or crawling sensation within your legs every day? How would you feel if you had to make various lifestyle changes because of constant body and leg restlessness?
People with restless leg syndrome (RLS) not only make lifestyle adjustments because of many uncomfortable symptoms they experience, but many must endure chronic symptoms that can take a toll on their quality of life. According to the National Institute of Neurological Disorders & Strokes, it has been estimated that roughly 7% to 10% of the U.S. population is impacted by RLS. Even though there’s currently no cure for this syndrome, there are natural treatment methods available like cannabis and cannabidiol that can help alleviate many RLS symptoms.
Background of Restless Leg Syndrome & Its Significant Impact on One’s Life
Restless leg syndrome is classified as a neurological disorder that can impact anyone of any age. However, this syndrome gets more severe and painful as one gets older even though it’s not life-threatening. Sometimes, RLS is referred to as Willis-Ekbom Disease or Wittmaack-Ekbom’s Syndrome. These names come from one of the first doctors who discovered and identified RLS, which was Dr. Karl-Axel Ekbom in 1943.
Generally, restless leg syndrome causes different symptoms with many of them occurring and worsening in the evening. Thus, sleeping difficulties often occur because this syndrome frequently wakes people up or it becomes so uncomfortable that they cannot fall asleep. As a result, numerous people with RLS have a poor quality of life and a decline in their overall well-being.
In addition, according to the National Sleep Foundation, some individuals describe RLS as the following, “…the sensation of ants crawling through their legs or carbonation running through their veins.” Normally, when an individual is relaxing, sitting, or lying down, their symptoms get progressively worse. The severity of this disorder differs per person though. Most people experience relief after moving around a lot. Whereas, others don’t find relief from movements at all.
Currently, the precise cause of RLS is unidentified. But, there are different conditions that are closely linked to it. Some people can even develop RLS from medication-causing side effects. Unfortunately, since the exact cause of RLS is yet to be identified, it’s difficult to prevent it.
Common RLS Side Effects and Painful Symptoms
Although RLS affects every individual differently, there are multiple side effects and symptoms that are felt by most RLS patients. The following symptoms are felt by most affected individuals:
• Sleeping difficulties and interruptions
• Daytime fatigue and sleepiness
• Restlessness, which can manifest into repetitive movements like tossing and turning in bed or pacing back and forth
• Tingling, itching, and/or crawling sensations within the legs
• A strong force to move and shake the legs to alleviate uncomfortable sensations
• Unintentional movements or leg jolting during one’s sleep cycle, while resting, or even while wide-awake
Additionally, physical side effects include sleep loss, daytime sleepiness, overall discomfort, itchiness, and leg restlessness. Because this disorder can cause discomfort at any time of the day or night, some individuals opt out of social gatherings and events because of the pain they experience when sitting or standing for lengthy periods of time. Therefore, various emotional symptoms occur like loneliness, anxiety, depression, and isolation. On the plus side though, different treatment methods are available to help those with RLS live the best life they can. One rapidly-growing natural treatment method that can help is cannabis and CBD.
Traditional and Non-Traditional RLS Treatment Methods: What’s Right for You?
In recent years, RLS has gained more attention. However, this disorder has been documented and examined for centuries. There are both traditional and non-traditional treatment methods available, and it’s up to the individual to decide what’s best for them. Several traditional RLS treatment methods include vein treatments, foot wrap treatments, pharmaceutical medications, and specific exercises on a regular basis. There are also non-traditional, natural methods available too. Some of these include calf massages, warm and cold compresses, ice packs, warm baths, and cannabis and CBD products.
How Cannabis and Cannabidiol Usage Can Help Alleviate RLS Symptoms
Moreover, one 2017 study discovered that inhaled medicinal cannabis lessened RLS symptoms. Five out of the six subjects experienced full symptom remission after consuming cannabis, and CBD played a large role in symptom alleviation. After the cannabis treatment ended, all participants experienced sleep improvements. Another study found that Sativex (a sublingual cannabis-based spray that contains CBD and THC) helped 40-50 percent of the RLS patients with their sleeping issues. Fortunately, cannabis and CBD can help treat insomnia, but especially CBD, which often delivers sedative and mellow effects to users.
So far though, there’s a lack of clinical trials and studies on the topic of medicinal cannabis helping treat RLS. However, there are numerous anecdotal success stories that RLS patients continue to share. Due to cannabis and CBD’s analgesic properties, RLS patients who experience regular pain can find relief from consuming different cannabinoids. Also, because of the relief that’s delivered from cannabis, individuals can relax more easily, which results in better bedtime preparation to combat insomnia.
Also, due to the sleeping difficulties most RLS patients experience, other problems could arise like anxiety, depression, lessened mental functioning, and wear and tear to the body’s immune system. Fortunately, though, CBD contains natural anti-anxiety and anti-depressant properties. This cannabinoid can also provide the body with antioxidants, which can help improve one’s immune system.
Optimal Cannabis Strains to Alleviate RLS Symptoms
On another note, there are various cannabis strains that can be consumed to help alleviate RLS symptoms. The strains individuals use should be appropriate to the symptoms they want treated though. If RLS patients want to use cannabis to help with insomnia, high THC or high CBD strains are recommended. A few examples of these include granddaddy purple (indica), purple kush (indica), ACDC (hybrid and high CBD), and Charlotte’s Web (high CBD). All these strains can help alleviate pain, anxiety, and insomnia while also delivering physically and mentally relaxing effects.
Then, for nearly immediate relief, the best consumption methods include inhalation, sublingual administration, and topical usage. All in all, it’s essential to find the right cannabis strain and consumption method that’ll fit one’s exact needs and wants.
Although restless leg syndrome impacts twice as many females as males, it can still be detrimental to one’s quality of life regardless of their gender. If traditional treatment methods are ineffective or do more damage than good, it may be a sign to try something more natural like cannabis and/or Cannabidiol. If you could naturally improve your well-being and alleviate many painful chronic symptoms, would you?
*** BREAKING NEWS ***
For the first time in history, a congressional committee has approved a bill to end federal marijuana prohibition. The House Judiciary committee passed the Marijuana Opportunity, Reinvestment and Expungement Act in a 24-10 vote, setting the stage for a full floor vote. This is the first step toward removing cannabis from the Controlled Substances Act.
Doctor Eric I. Mitchell just sent this article this morning.
Full Spectrum Hemp Oil w/VitaminCBD™ and Its Fight Against Inflammation
“Have You Had Your VitaminCBD™ Today for Your Mental Clarity and Your Bone Health”
Full Spectrum Hemp Oil (FSHO) with VitaminCBD™ was grown by a retired Orthopaedic Surgeon in the organic fields of Maine and processed into a tincture with the main purpose of affecting the bone stimulation problem to combat OSTEOPOROSIS. This doctor’s research in bone stimulation goes back to 1975 when as a post-doctoral Orthopaedic fellow at the Perelman School of Medicine at the University of Pennsylvania. Fast forward, transforming from Orthopaedic Surgeon to farmer under the 2014 Farm Bill, he named and trademarked the first Vitamin of the Endocannabinoid System, VitaminCBD ™ on December 20, 2018, the day the farm bill was passed making Hemp a legal crop for the first time in 49 years.
VitaminCBD™ (Cannabidiol) as I have defined it, is emerging as a powerful supplement with a significant effect on our body’s Endocannabinoid System (ECS). The ECS has been shown to have a strong effect on the inflammatory, immune, cognitive and motor systems of the body. VitaminCBD™ is one of over 100 cannabinoids, natural compounds found in Cannabis sativa L known as hemp when there is less than .3% by weight of THC, which makes it a non-scheduled compound in accordance with the DEA.
The ECS is perhaps the most important physiologic system involved in establishing and maintaining human health. Endocannabinoid receptors are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells. Endocannabinoid receptors known as CB1 and CB2 are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells. In each tissue, the cannabinoid system performs different tasks, but the goal is always the same: homeostasis or balance.
This cannabinoid has shown promising results in independent research and studies as a treatment for a variety of conditions including antiemetic, anticonvulsant, antipsychotropic, anti-inflammatory, antioxidant, anti-tumoral, anti-anxiolytic/antidepressant, and more. With the growing prevalence of autoimmune diseases in the world, there is a huge need for therapies that improve and restore balance to immune function, without suppression. Cannabinoids found within full spectrum hemp oil have shown promising results for the improvement of autoimmune and inflammatory diseases.
The word inflammation is the word that keeps coming up, over and over again. In the November edition of the AARP magazine the cover story is a five-page article on research linked to inflammation as a common link to nearly every critical disease of aging lifestyle, called “low grade inflammation”. The new research, which drew from the VITAL study, aimed to determine the biomarker levels of several inflammation indicators in people either taking or not taking vitamin D and omega-3 fatty acid supplements, or fish oil for the purpose of reducing inflammation. There were no vital markers seen after one year thereby reducing inflammation.
So, inflammation is a key prognostic marker of multiple life-threatening conditions — especially those associated with aging and obesity. These include cardiovascular disease, heart failure, osteoporosis, some neurodegenerative conditions (including Alzheimer's disease), diabetes, and some cancers.
FSHO with VitaminCBD™ is not a cure all and I make no medical claims, however it is the ongoing research which is pointing to the needed balancing of our ECS which is critical in cellular health.
“Have You Had Your VitaminCBD™ Today for Your Mental Clarity and your Bone Health”
Eric I. Mitchell, MD, MA, FACPE, CPE
President
Hemp Commodity Industries, LLC
Cannabinoids are currently used in cancer patients to palliate wasting, emesis and pain that often accompany cancer. A significant advancement in cannabinoid use in cancer treatment came from the discovery of a potential utility of these compounds for targeting and killing cancer cells.
Multiple sclerosis and spinal cord injury, neuropathic pain, cancer, atherosclerosis, stroke, myocardial infarction, hypertension, glaucoma, obesity/metabolic syndrome and osteoporosis are some of the diseases in which alterations in the eCB system have been demonstrated, thus paving the way for new therapeutic strategies aimed at restoring normal eCB system functionality.
Currently, the term ‘cannabinoid’ refers to more than 100 terpenophenols derived from Cannabis sativa, as well as to synthetic compounds that directly or indirectly interact with cannabinoid receptors.
Cannabinoids are currently used in cancer patients to palliate wasting, emesis and pain that often accompany cancer. A significant advancement in cannabinoid use in cancer treatment came from the discovery of a potential utility of these compounds for targeting and killing cancer cells. In 1975 Munson et al. demonstrated the administration ofTHC and cannabinol inhibited the growth of Lewis lung adenocarcinoma cells in vitro as well as in vivo after oral administration in mice. The interest in anticarcinogenic properties of cannabinoids was renewed after the discovery of the eCB system and the cloning of the specific cannabinoid receptors. Since then, several cannabinoids have been shown to exert anti-proliferative and pro-apoptotic effects in various cancer types (lung, glioma, thyroid, lymphoma, skin, pancreas, uterus, breast, prostate and colorectal carcinoma) both in vitro and in vivo. Moreover, other antitumourigenic mechanisms of cannabinoids are currently emerging, showing their ability to interfere with tumour neovascularization, cancer cell migration, adhesion, invasion and metastasization.
However, the clinical use of THC and additional synthetic agonists is often limited by their unwanted psychoactive side effects, and for this reason interest in non-psychoactive phytocannabinoids, such as CBD, has substantially increased in recent years. Interestingly CBD has no psychotropic activity and, although it has very low affinity for both CB1 and CB2 receptors, it has been recently reported to act with unexpectedly high potency in vitro as antagonist of CB1 receptors in the mouse vas deferens and brain tissues.
Furthermore, CBD can be considered as an alternative agent for breast cancer therapy, and CBD has actually been shown to shrink and kill breast cancer cells.
CBD also possesses anti-tumoural properties in the treatment of glicoma. Interestingly, combined treatment of THC with CBD demonstrated that CBD enhanced the THC inhibitory effect on glioblastoma cell growth. Thus, actually curing the glicoma.
CBD and leukemia/lymphoma. Research Results suggest CBD, acting through CB2 receptors and ROS production, may represent a novel and highly selective treatment for leukemia. Moreover, previous evidence indicated that human leukemias and lymphomas expressed significantly higher levels of CB2 receptors compared with other tumour cell lines, suggesting that tumours of immune origin may be highly sensitive to the CB2-mediated effects of CBD.
CBD and lung cancer. Research findings suggest a novel mechanism underlying the anti-invasive action of CBD on human lung cancer cells and imply its use as a therapeutic option for the treatment of highly invasive lung cancers.
Colon cancer is a major cause of morbidity and mortality in Western countries. Research suggests CBD might be worthy of clinical consideration in colon cancer prevention.
Conclusion and future directions
Evidence is emerging to suggest that CBD is a potent inhibitor of both cancer growth and spread.
Interestingly, the anticancer effect of this compound seems to be selective for cancer cells, at least in vitro, since it does not affect normal cell lines. The efficacy of CBD is linked to its ability to target multiple cellular pathways that control tumor growth through the modulation of different intracellular signaling --- dependent on the cancer type.
Finally, the use of CBD/Sativex can be suggested in combination with classical chemotherapeutic agents to check for the presence of a synergistic effect that might potentially allow clinical chemotherapeutic dose reduction, thereby reducing toxicity while maintaining efficacy. In the light of its safety record and considering that CBD is already currently used in patients with multiple sclerosis, the findings here summarized suggest that CBD might be worthy of clinical consideration for cancer therapy.
What this research suggests is that cannabis whether CBD alone or in combination with THC can be an effect treatment for some of the most profound illnesses facing modern medicine. Furthermore, the limits of medicinal uses for cannabis may be far more extensive and far reaching than anyone knew. Thus, UNVC and other companies developing treatments and orphan drugs based on the cannabis molecules may not yet know their limitations. To suggest the medicinal benefits derived from cannabis is exponential is very likely putting it mildly.
British Journal of Clinical Pharmacol. 2013 Feb; 75(2): 303–312.
Published online 2012 Apr 17. doi: 10.1111/j.1365-2125.2012.04298.x
PMCID: PMC3579246
PMID: 22506672
Cannabidiol as potential anticancer drug
Paola Massi,1 Marta Solinas,2 Valentina Cinquina,2 and Daniela Parolaro2
Kgem
How Mapping Marijuana DNA Could Change the Future of the cannabis industry
Scientists are currently in the midst of exploring uncharted territory: The cannabis genome. Unlike with other plants, researchers don’t have a long history of closely analyzing the genetic makeup of the plant. But for the past seven years – as more and more states legalize medical and recreational pot – researchers have been developing a high-quality marijuana genome. Everyone from low-level researchers to larger companies are part of this effort, and they say mapping the cannabis genome could be highly beneficial to people who grow or use cannabis.
“No one has any idea what they’re smoking. Everything is name draw, so consumers and patients don’t know what they’re getting,” says Mowgli Holmes, co-founder and CEO of Phylos Bioscience, which has been working on its cannabis genome for over two years. “DNA sequencing uniquely identifies a plant, which allows growers to really tell their customers what plant they’re actually getting.” The plants genetics control what chemicals the plant is going to make.
Phylos Bioscience released its first reference genome for cannabis at the end of 2016. Phylos has a program where cannabis growers can send samples of their plants to the company to get the plant’s genetic information, which helps growers, and also helps the company add more genetic data to its genome. “We’ve now sequenced thousands of different plants, and we have by far the biggest database of individual plant data.
Sean O’Connor, a law professor who focuses on intellectual property at the University of Washington, says “If we get federal legalization… you’re definitely going to see both recreational and pharma coming in and trying to patent what they can. Pharmaceutical companies will be able to isolate strains of cannabis DNA and then create compounds found in cannabis in the lab, and that will result in patents for many drugs based on their creations. This is big folks, and it changes everything.
Some of the most exciting but controversial research is in isolating and identifying cannabinoids and particular chemical compounds, not THC that gets you high but other things that could have therapeutic benefits, and then researchers will just generate that chemical. They no longer need the whole cannabis plant. What you’ll see is a pharmaceuticalization of medical marijuana.
http://datatrekresearch.com/mapping-the-cannabis-genome/
Chief scientific officer Jonathan Page of one of the biggest marijuana companies in the world, Aurora Cannabis, said it “was a very tough nut to crack scientifically.” Ultimately, it took several years, “a new kind of ‘long read’ sequencing technology, and a loosening of federal regulations that allowed researchers to handle cannabis DNA.
THC and CBD are just two cannabinoids from the cannabis sativa plant, but there are others that also reportedly have therapeutic benefits. Ideally, companies will be able to take cannabinoid-production genes, “transfer the DNA into yeast or bacteria growing in large tanks, feed the genetically modified microbes a steady diet of sugar, and derive pure tinctures of many obscure cannabinoids with supposed therapeutic properties --- for those familiar with this process, it is akin to brewing beer.
According to CEO and chairman of Canadian marijuana producer Cronos Group Mike Gorenstein, “there are rare cannabinoids that you just can’t get from the plant in any commercial quantity.” That’s why the company partnered with biotech firm Ginkgo Bioworks to “produce eight cultured cannabinoids for use in the pharmaceutical and nutraceutical markets.
Cofounder of Inplanta Biotechnology, Darryl Hudson, believes “genetic modifications will be the ‘next wave’ of cannabis breeding.” The Director of Genetics Research Rob Roscow at Canopy Growth even “claims to have developed a method for making THC-free and CBD-free plants via precision gene editing of the relevant genes.
The Chief Scientific Officer at Trait Biosciences, Richard Sayre, has discovered a way to boost cannabinoid levels within the leaf tissue of the plant that will create a tremendous increase in yield while also cutting harvest time.
https://www.pnas.org/content/116/18/8638
If you understand how the genotype works you can grow the plants with the traits you want much faster and with extreme precision. Called marker-assisted selection, it’s the key to modern agriculture. In order to understand your genotype you have to map out the genetic structure, or genome of the plant. In the case of cannabis, this involves mapping out 800 million base pairs across 10 chromosomes to build the genomic map.
http://www.mesaorganics.com/blog/medical/mapp...is-genome/
When we think about all the medical breakthroughs being made with just a handful of cannabinoids the implications of mapping the entire cannabis genome are truly staggering. Practically any purpose cannabis is grown for can be enhanced.
http://www.mesaorganics.com/blog/medical/mapp...is-genome/
Kgem
UNVC investors need to do serious research to find the answers to many developments now occurring in the cannabis industry.
If you are an investor, entrepreneur, manufacturer or retailer, the national legalization of hemp and CBD has opened a world of opportunities – each with their own questions: “What is the impact of mass market retailers entering the market? How are businesses navigating regulatory gray areas? What are the obstacles and opportunities across the hemp & CBD supply chain? How are new processing techniques based on the molecular mapping of the cannabis molecule affecting the industry? Yes, the cannabis molecule has been mapped, and new elements have been discovered. What does this mean for investors? Can you even imagine a new treatment for cancer or for that matter even a cure?
I suggest research can now be done without the need to actually have cannabis in the laboratory. Furthermore, orphan drugs may now be developed that the FDA otherwise may not have approved. With individual elements now mapped, will THC in its molecular form even be necessary?
Lots going on that most do not know, and the impact of this technology is yet to be discovered by most investors. Perhaps investors should stop their speculation of riches and actually research how new discoveries could affect their investments.
Kgem
Recent Research Studies and implications for UNVC
Addiction
Of 21 patients on opioid pain medications for post-traumatic concussions, 38% of patients decreased or discontinued their pain medications when treated with medical cannabis. (Neurology, 2019)
In states where marijuana is available through medical channels, a modestly lower rate of opioid and high-risk opioid prescribing was observed. Medical marijuana legalization was associated with a lower odds of any opioid use: OR?=?0.95 (0.94–0.96), chronic opioid use: OR?=?0.93 (0.91–0.95), and high-risk opioid use: OR?=?0.96 (0.94–0.98). (Journal of Internal Medicine, 2019)
Thirty-two (32%) percent of people who try tobacco become dependent, whereas 15% who try alcohol and only 9% who try marijuana become dependent. (Berkeley Journal of Criminal Law, 2018)
Owing to substantial methodological issues, previous epidemiological and clinical studies examining marijuana smoking on the risk of tobacco-sensitive lung diseases (e.g., lung cancer and chronic obstructive pulmonary disease [COPD]) have not produced consistent results. (Canadian Medical Association Journal, 2018)
There is emerging scientific evidence indicating that marijuana can serve as a pathway away from dependency of more dangerous substances, including prescription drugs, heroin, and alcohol. (Berkeley Journal of Criminal Law, 2018)
Administration of a therapeutic dose of CBD (750?mg) showed significantly low abuse potential in a highly sensitive population of polydrug users. (Epilepsy Behavior, 2018)
States permitting medical marijuana dispensaries experience a relative decrease in opioid addictions and opioid overdose deaths (RAND BING Center for Health Economics, 2015)
Cigarette smokers who used CBD smoked approximately 40% fewer cigarettes when using CBD. (Addictive Behaviors, 2013)
Unlike other addictions, cannabis dependence of mild to moderate severity is not associated with dopamine release alterations in the brain. However, earlier or longer duration of use is related to lower dopamine release. These observations suggest a more harmful effect of using marijuana during adolescence. (Biological Psychiatry, 2012)
Aging Effects
In one small study of ten women with severe dementia, an oral cannabis extract with THC/CBD, in higher doses than in other studies, was well tolerated and greatly improved behavior problems, rigidity, and daily care. (Medical Cannabis and Cannabinoids, 2019)
64% of seniors rated their quality of life as “good” after using CBD, up from 31.1% prior to using CBD. (Remedy Review, 2018) 61.1% of seniors who tried CBD reported reduced pain. (Remedy Review, 2018)
45.6% of seniors who used CBD said it improved their sleep quality. (Remedy Review, 2018)
7.8% of seniors reported CBD improved their cognitive function. (Remedy Review, 2018)
5.6% of seniors who tried CBD reported decreased blood pressure. (Remedy Review, 2018)
Overall, 28.9% of CBD users over age 54 claimed it was “extremely effective” at treating symptoms.(Remedy Review, 2018)
Findings from a small study suggest that, when carefully matched on baseline variables and not differing in IQ or alcohol use, young, near-daily cannabis users do not differ from non-using control subjects in prospective memory performance. (Frontiers in Psychology, 2018)
Patients with dementia-related agitation and appetite loss who were treated with dronabinol – a cannabinoid – (average dosage =7.03 mg/d) experienced significant reductions in all aspects of agitation, including aberrant vocalization, motor agitation, aggressiveness, and treatment resistance (p <.0001), but no significant improvements in appetite. (Am J Geriatr Psychiatry, 2014)
Anxiety
Among people using benzodiazepines (commonly prescribed to reduce anxiety) who took CBD, 45.2% were able to stop using benzodiazepines. (Cannabis and Cannabinoid Research, 2019)
THC or CBD given in addition to other pharmacotherapies and psychotherapy improved specific symptoms of some disorders (e.g. in dementia, cannabis and opioid dependence, schizophrenia, general social anxiety, post-traumatic stress disorder, anorexia nervosa, attention-deficit/hyperactivity disorder, and Tourette`s disorder). (European Archives of Psychiatry and Clinical Neuroscience, 2019)
High-dose oral CBD (150–600 mg/d) may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation (Cannahealth, 2019)
https://www.cannahealth.org/cbd-cannabis-statistics/
CBD in the NBA
The National Basketball Association (NBA) prohibits players from using marijuana, but not specifically CBD. Players are randomly tested up to four times throughout the season and the threshold for a positive test is 15 nanograms of THC per milliliter. After the first infraction, players must participate in a substance-abuse program. After a second positive test, players are subject to a maximum $25,000 fine. A five-game suspension is imposed after a third violation.
The good news is that now there’s been some rumblings among NBA officials about changing the league’s stance on marijuana.
Luckily, NBA players can experience the natural benefits of CBD and not violate league rules by avoiding products containing THC. Retired NBA player Al Harrington discovered the natural benefits of CBD toward the end of his playing career and has said he believes today’s players could benefit from regular CBD supplements.
I am told some of the top NBA players will soon be endorsing some of our favorite CBD products. Stay tuned.
Why Would Pro Athletes Take CBD Oil?
Many pro athletes have found CBD supplements beneficial for keeping their bodies healthy and capable of performing at a high level. If you’ve trained seriously for any sport, you know how the intensity of training can place an enormous level of stress on the body. Now imagine being a professional athlete, where you’re constantly pushing your body to its peak.
Derived from cannabis plants like hemp, CBD oil is a botanical extract that is naturally abundant in CBD. CBD, or cannabidiol, is an all-natural cannabinoid that interacts with our body’s endocannabinoid system, a regulatory network that keeps many of our functions in balance.
Athletes in the NFL, NBA, MLB, and NHL have found that CBD supplements offer an all-natural way to keep their body at their best and boost performance. Sleep, metabolism, and immune response are just some of the functions important to athletes that the endocannabinoid system is responsible for keeping in homeostasis.
CBD is an ideal cannabinoid solution for athletes, because it’s non-psychoactive, non-addictive, and won’t impact performance by causing a high or any adverse side effects.
https://cbdoilreview.org/cbd-cannabidiol/cbd-in-sports/
Raphael Mechoulam speaks about his research regarding the structure of cannabis compounds and his latest discoveries
Sept. 26, 2019, 11:44 AM CDT
By Noah Smith
Raphael Mechoulam, an Israeli organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, remembers the letdown after his groundbreaking discoveries surrounding the structure of the cannabis compounds CBD and THC in 1963 and 1964, followed by clinical tests with CBD published in 1980.
Not much happened,” Mechoulam said, noting that it would take more than 30 years before his clinical work on using CBD, or cannabidiol, to treat epilepsy became widely accepted. Greenwich Biosciences, which is owned by GW Pharmaceuticals, was able to develop the first cannabis-derived drug that built on Mechoulam’s research. The drug, Epidiolex, treats seizures associated with two rare forms of epilepsy and was approved by the FDA only last year.
But even as his work laid the foundation for the modern cannabis industry and for understanding how cannabis interacts with the human body, a white whale eluded research: cannabis acids, which are compounds that are produced in the plant when it is alive and may be more potent than their better-known derivatives, such as CBD and THC.
That changed on Monday, when Mechoulam and a group of researchers announced at a medical cannabis conference in Pasadena, California, that they have developed a process for creating synthetic, stable acids that are found within the plant, and that the synthetic acids, which include acid versions of CBD and THC, are now available for licensing to companies for drug development.
The discovery paves the way for drug companies to potentially develop new drugs based on the acids for a variety of health issues such as psoriasis, arthritis, anxiety and inflammatory bowel disease.
The research is the product of a startup called EPM, in partnership with Mechoulam, six universities in Israel, the U.K. and Canada, the world’s largest topical cream company and a publicly traded laboratory company.
“I think it’s a big deal,” Mechoulam, who acts as EPM’s head of research, said, comparing it to his discoveries about CBD and THC.
In a 2018 British Journal of Pharmacology study, Mechoulam and his co-authors wrote that their synthetic compound, cannabidiolic acid methyl ester (called HU-580 in the paper) could be more effective than existing CBD remedies, making it “a potential medicine for treating some nausea and anxiety disorders.” Those initial clinical tests found the acids have yielded results on par, and even exceeding, existing treatments, without the side effects.
The naturally occurring but unstable CBD acid (CBDA) is a thousand times more potent than CBD in binding to a particular serotonin receptor thought to be responsible for alleviating nausea and anxiety.
“It’s an interesting molecule that potentially doesn’t have side effects,” said Dan Peer, managing director of the Center for Translational Medicine and head of the Cancer Biology Research Center at Tel Aviv University.
“It works like a steroid. If it doesn’t have adverse effects, then you have a replacement, which is great,” Peer said, discussing testing he did with cannabis acids and inflammatory bowel disease.
Ziva Cooper, research director of the UCLA Cannabis Research Initiative, said EPM’s research confirms what many in the field have long suspected about cannabis acids, but have been unable to confirm due to their instability.
“Their work is quite innovative, and it definitely builds on what we know related to the potential therapeutic effects of cannabinoids,” Cooper said, adding that the compound could be particularly effective for pain control. Cooper said that while more testing will be needed to determine effectiveness and safety for humans, EPM’s results so far are “quite encouraging.”
As the U.S. government plans to spend $3 million to research CBD, pharmaceutical industry veterans still urge caution, while lending some insight regarding why more drugs have not been built on cannabis compounds.
“People are always joking about getting the munchies if they use marijuana,” said David Campbell, a partner at the consulting firm Oliver Wyman and advisor to EPM, who has more than two decades of experience in the pharmaceutical industry.
Campbell said such anecdotal evidence is a “far cry” from being able to convince a research committee or shareholders about the efficacy of cannabis to treat a condition.
“The drugs that are produced are just not potent enough,” said Peer, referring to the CBD, THC, and other nonacids.
These factors, in addition to social mores, have all led to a situation where pharmaceutical companies have not been a major presence in cannabis development.
https://www.nbcnews.com/tech/innovation/canna...1059116?mc
Arthritis Foundation issues CBD guidance, a first among major patient advocacy groups
Published September 24, 2019
The Arthritis Foundation became the first major patient advocacy group to issue CBD recommendations, telling some 50 million arthritis patients Tuesday what to look for when choosing CBD.
The group did not recommend using CBD to treat arthritis symptoms, though it noted that people with arthritis show “significant use of and interest in CBD” for pain relief.
“We are intrigued by the potential of CBD to help people find pain relief,” the foundation said, calling for the U.S. Food and Drug Administration to “expedite the study and regulation of these products.”
The Arthritis Foundation told members that “no serious safety concerns have been associated with moderate doses” of CBD. But the group also warned that CBD products can interact with many medications commonly prescribed for arthritis.
The group gave arthritis patients guidelines for choosing CBD products. Among the recommendations:
• Avoiding CBD products with THC. “Be aware that THC, even at low levels, may get you high, creating cognitive, motor and balance issues,” the group said.
• Using only CBD products produced in the U.S. from domestically grown ingredients.
• Avoiding vaporized CBD products entirely, especially people with inflammatory arthritis.
• Buying products from companies that test each batch and provide results.
• Talking to a physician before trying CBD. “Be aware that marketers and people behind retail counters are not health professionals; they are salespeople,” the group warned.
• Checking state law to see which CBD products are considered legal.
https://hempindustrydaily.com/arthritis-foundation-issues-cbd-guidance-a-first-among-major-patient-advocacy-groups/?utm
Where we stand today.
The entire cannabis industry is suffering a major downturn of late, and Univec is no exception. Doctor Dalton stated, “Sometimes to finish first is to be last.” What does Dalton mean by that statement? Perhaps he is saying he will be the last man standing when all is said and done. Months ago I talked about the high flyers of today may no longer be around in just a year or so. Well, today we are at an inflection point where new leaders will soon be crowned. We've seen this once before during the Dot.com era.
What changes are expected that will lead this industry forward? This week we expect the Safe Banking Act to be passed in the United States Congress, and in Canada they are about to legalize edibles. The need for the Safe Banking Act should be self-explanatory for anyone aware of the issues, and legalizing edibles is said to be a real game changer in Canada. Legalizing edibles in Canada will also place pressure on the FDA to formulate new rules governing such products in this country as well. So stay tuned. This industry is about to get a much needed shot in the arm once again.
As Doctor Dalton said, it only takes one to know what is going on. In this case, that person is Doctor Dalton.
Kgem
Feds Award $3 Million In Grants To Study Marijuana Ingredients As Alternatives To Opioids
Published
September 19, 2019
By
Kyle Jaeger
The federal government has awarded $3 million in grants for research into the therapeutic benefits of ingredients in marijuana other than THC, emphasizing their potential as alternatives to prescription opioids.
In a notice published on Thursday, the National Institutes of Health (NIH) explained why the studies were necessary and listed grant recipients and the subjects they will investigate. That includes research into the use of CBD for arthritis pain, which will be led by New York University School of Medicine.
“The treatment of chronic pain has relied heavily on opioids, despite their potential for addiction and overdose and the fact that they often don’t work well when used on a long-term basis,” Helene Langevin, director of the National Center for Complementary and Integrative Health (NCCIH), said in a press release. “There’s an urgent need for more effective and safer options.”
A total of nine grants were issued, with NIH stating that the funds will help identify alternative treatment options for pain and provide information about the impact of consuming cannabis compounds such as CBD and other lesser-known cannabinoids as well as terpenes found in the plant.
“The cannabis plant contains more than 110 cannabinoids and 120 terpenes, but the only compound that’s been studied extensively is THC,” the press release said.
But while THC is known to treat certain forms of pain, NIH is concerned that its intoxicating effects limit its medical applicability.
“THC may help relieve pain, but its value as an analgesic is limited by its psychoactive effects and abuse potential,” David Shurtleff, deputy director of NCCIH, said. “These new projects will investigate substances from cannabis that don’t have THC’s disadvantages, looking at their basic biological activity and their potential mechanisms of action as pain relievers.”
NIH first announced that it would be issuing grants for studies into minor cannabinoids and terpenes last year.
Federal health agencies aren’t the only institutions interested in learning about marijuana compounds other than THC. On Wednesday, a Senate committee issued a spending report that called for research into CBD and CBG while also criticizing the federal drug scheduling system for inhibiting such research.
Read descriptions of the federal cannabinoid and terpene research grant awards below:
Mechanism and Optimization of CBD-Mediated Analgesic Effects; Boston Children’s Hospital, Boston,; Zhigang He, Ph.D., B.M., and Juan Hong Wang, Ph.D. This project will investigate how the pain-relieving effects of cannabidiol (CBD) and other minor cannabinoids may be modulated by the activity of potassium-chloride cotransporter 2 (KCC2), a chloride extruder expressed in most neurons. (Grant 1R01AT010779)
Neuroimmune Mechanisms of Minor Cannabinoids in Inflammatory and Neuropathic Pain; University of California, San Francisco; Judith Hellman, M.D., and Mark A. Schumacher, M.D., Ph.D. This project will explore the effects of minor cannabinoids on inflammatory and neuropathic pain in vitro and in vivo, focusing on the interactions of the cannabinoids with the peripheral receptor called TRPV1 and a cannabinoid receptor, CB1R. (Grant 1R01AT010757)
Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics; Research Triangle Institute, Research Triangle Park, North Carolina; Jenny L. Wiley, Ph.D. This project will evaluate purified biosynthesized minor cannabinoids and selected terpenes alone and in planned combinations to determine their potential efficacy as pain relievers against acute thermal, inflammatory, neuropathic, and visceral pain. (Grant 1R01AT010773)
Identifying the Mechanisms of Action for CBD on Chronic Arthritis Pain; New York University School of Medicine, New York City; Yu-Shin Ding, Ph.D. This project will use neuroimaging studies and behavioral assessments to investigate the mechanisms of action of CBD in the modulation of chronic pain associated with osteoarthritis in a mouse model. (Grant 1R21AT010771)
Synthetic Biology for the Chemogenetic Manipulation of Pain Pathways; University of Texas, Austin; Andrew Ellington, Ph.D. This project will use a novel method to evolve individual variants of cannabinoid receptor type 2 (CB2) that interact with high affinity with minor cannabinoids and evaluate the new variants in a mouse model of pain. (Grant 1R21AT010777)
Exploring the Mechanisms Underlying the Analgesic Effect of Cannabidiol Using Proton Magnetic Resonance Spectroscopy; University of Utah, Salt Lake City; Deborah A. Yurgelun-Todd, Ph.D. This project will use proton magnetic resonance spectroscopy (1H-MRS) to evaluate changes in brain chemistry in critical pain-processing regions after short-term administration of a cannabis extract enriched in CBD. (Grant 1R21AT010736)
Mechanistic Studies of Analgesic Effects of Terpene Enriched Extracts from Hops; Emory University, Atlanta; Cassandra L. Quave, Ph.D. This project will take a multidisciplinary approach to investigate the analgesic effects of terpenes from Humulus lupulus (hops), a plant that is closely related to cannabis and has a very similar terpene profile. (Grant 1R21AT010774)
Systematic Investigation of Rare Cannabinoids With Pain Receptors; University of Illinois at Urbana-Champaign; David Sarlah, Ph.D. This project involves synthesizing several classes of rare phytocannabinoids, systematically evaluating their anti-inflammatory potential, and examining the effects of the compounds with the strongest anti-inflammatory potential on the major receptors involved in pain sensation. (Grant 1R21AT010761)
Analgesic efficacy of single and combined minor cannabinoids and terpenes; Temple University, Philadelphia; Sara J. Ward, Ph.D. This project will use rodent models of pain to evaluate the effects of four biologically active components of cannabis that may act synergistically to protect against pain development and to assess the interactions of these four substances with morphine. (Grant 1R01AT010778)
https://www.marijuanamoment.net/feds-award-3-...b3ce9f3d94
Univec investors should familiarize themselves with CBD elements that provide some of the most exciting medical benefits. Many of these benefits have only recently been discovered.
Hemp Flavonoids
About 20 different flavonoids have been found in cannabis plants*. The distinct smell, color, and taste of certain hemp strains? That’s the flavonoids working. The exact makeup of flavonoids is different from strain to strain, so all 20 flavonoids may or may not be present in every hemp product. The three most common are quercetin, apigenin, and cannflavin.
• Quercetin: Part of the flavonol class, quercetin is associated with antioxidant, anti-viral, and anti-cancer effects.
• Apigenin: A member of the flavone class with potential anti-anxiety and anti-inflammatory effects.
• Cannflavin: Flavones, classified as cannflavins A, B, and C. Cannflavin A and cannflavin B are potential anti-inflammatories.
Hemp and Cannflavin
The cannflavins are worth a bit of special attention, given that they are only found in cannabis plants. They are prenylflavonoids, belonging to yet another sub-class of flavonoids.Cannflavins A and B were isolated in Cannabis sativaL. plants in the 1980s. Cannflavin C was isolated in 2008, so it hasn’t been researched as extensively yet.
One study found that cannflavins are potent anti-inflammatories, with activity thirty times greater than asprin. The study says “cannflavins A and B act to inhibit the in vivo production of two pro-inflammatory mediators, prostaglandin E2 and the leukotrienes.”
For those of us who aren’t up on our medical sciences, in vivo refers to effects that take place in a living organism. Leukotrienes are involved in the development of inflammatory diseases like asthma and rheumatoid arthritis, and prostaglandin E2contributes to inflammatory pain. Cannflavins A and B are shown to help stop the production of these two compounds in the body.
While we often focus on studies related to CBD and other cannabinoids, cannflavin shows promise on its own, and provides more insight into why so many advocates recommend whole-plant, full-spectrum products. The potential anti-inflammatory effects of cannflavin is certainly not something you’d want to leave on the table.
Flavonoids and the Entourage Effect
Regular readers will be familiar with the "entourage effect." This is the common name given to the unique synergy between cannabinoids, terpenes, flavonoids, and other phytonutrients in hemp products. As a quick refresher, all phytonutrients—even in trace amounts—contribute to the effectiveness of others.
As an example, CBD on its own has a relatively low effective dosage threshold. When administered in a full-spectrum format with the full range of cannabinoids, flavonoids, and terpenes, there was seemingly no dose level at which CBD’s effects plateaued .
Researchers suggest the differences in the presence of all phytonutrients—and not just cannabinoids— across hemp strains contribute to the reported varying effects of different products. Therefore, future research into the medicinal value of C. sativa plants can’t just focus on CBD to THC ratios. The entire picture must be considered, including terpenes and flavonoids.
Testing for Flavonoids in Hemp
Unfortunately, flavonoid testing is one area in which the hemp industry still needs to grow. Most commercial labs do not test for flavonoid content, only cannabinoids and sometimes terpenes. Public attention isn’t as focused on flavonoids, either. Terpene content is becoming the trendy thing to discuss, while another potentially beneficial compound class is forgotten. Focusing more on flavonoids will open up another avenue to understanding the hemp plant and to creating more effective products.
For instance, some flavonoids are understood to degrade or break down entirely under certain circumstances. Fruit and vegetable flavonoids are often found on the skin and outer layers. These flavonoids can be affected by storage conditions and preparation methods: onions stored at room temperature lose a third of their flavonoids in two weeks, and 80% of all flavonoids can be lost during the cooking process. As a rule of thumb, if the color fades during the cooking process, phytonutrients are being lost.
Which brings up a number of questions for hemp products. Will certain extraction methods degrade phytonutrients at a greater rate? Is there a way to preserve flavonoids in consumer products for a long period of time? Can farmers naturally create hemp strains that are more resilient to flavonoid loss?
We don’t have answers to these and many more questions, which is why it is so encouraging that more and more academic labs are focusing on researching the entire plant, and not just cannabinoids.
https://apotheca.org/6105-2/
Doctor Mitchell posted a brief history of cannabis and where we are today this morning. I assume this is in preparation for his meeting with law makers on September 11, 2019.
Cannabis Greater Than and Less Than
Words are vitally important when you decide to tell a story. Words have to match the audience you are writing to. This is a short story about Cannabis. First, you have to make sure that your audience understands what subject you are writing on if a new subject. So, an explanation might be necessary if it is a new subject which may not be an everyday subject matter. Cannabis is one of those subjects which has come into recent prominence with a lot of misunderstanding mainly because of the words people use, that do not tell the correct history and story.
The proper name for Cannabis is Cannabis sativa L. I will go with the short version Cannabis. It is an important annual herbaceous flowering plant indigenous to eastern Asia but now has a cosmopolitan distribution due to widespread cultivation over 100 years. Cannabis has had a long and sometimes bumpy history which extends from China 5000 BC to the new world of the Americas 1620 AD in its making and landing on our shores with the pilgrim’s arrival.
Cannabis has been cultivated throughout recorded history and used as a source for three main reasons, fiber, seeds or oil. Its extended use history includes food, recreational moods, religious and spiritual moods and medicine. The plant fell into American disfavor in the early 20th century when it was vilified and labeled as a poison in the 1930s and criminalized in the 1970s. The reasons for Cannabis disfavor are another rabbit hole for another blog at another time!
The Cannabis debate was fueled with word selection going back to the 1937 Marijuana Tax Act. The word Cannabis was substituted for this word, Marijuana, which was Spanish in origin and misspelled in English, Marihuana. Cannabis had already been in our US medicine cabinets for almost 100 years, so this name change was very important to title the bill with specific direction, however, the name Marijuana is not mentioned in the body of the 1937 bill. The word Cannabis sativa L was imprinted, by name, which would freeze both general application for industrial and/or medical purposes. When you could not pronounce the Spanish or English rendition of this new word then other names were given, Weed, Pot, Mary Jane, etc.
The recurrent debate over Cannabis caught fire when the 1970 War on Drugs ignited a debate on whether to look at this plant as two different plants, one for industrial purposes and the other plant as a medicine or drug. The confusion on the government’s part went back and forth. While that was concussing and a flip flop occurred multiple times in the Halls of Justice. Here come the important words. Cannabis is cannabis!
Each part of this same plant, Cannabis sativa L can be grown and harvested for different purposes, depending on its end use outlined in the third paragraph. The species was first classified by a word "sativa" which means things that are cultivated. What was not understood or clear was when the chemical properties in this plant changed to a point where it became subject to abuse. It was 1906 that Cannabis was called a poison and classified as a narcotic via the Uniform State Narcotic Drug Act, where 35 states had it listed as such. The Marihuana Tax Act of 1937 demonetized this crop with this expensive tax levy and trade embargo. Growing the Cannabis crop came to a halt and medical research stopped.
The 1937 tax act did not make Cannabis illegal. However, the whole plant was then criminalized and made illegal with the 1970 Controlled Substances Act and denoted as a Schedule 1 drug like heroin and cocaine. Well, fast forward to 2018. The slow crawl back into its rightful status as an incredible botanical got relief with the signing of the 2018 Farm Bill. Once again, The Farm Bill divided the plant back into two categories, Cannabis with Greater than 0.3% by weight, and Cannabis with Less than 0.3% by weight. The greater than 0.3% is still illegal and the less than 0.3% is in a renaissance for its medicinal remedies and the subject of my next blog. So, get your wording correct, with greater than and less than, so we all know what story you are telling.
Eric I. Mitchell MD.
Perhaps this is what Dalton was referring to when he talked about DEA Research Contracts
DEA Grants MedPharm One of the First Federal Cannabis Research Licenses to Grow Marijuana
Published last week on
August 28, 2019
By
Ella Hughes
MedPharm Research is one among the first applicants who was given the green light and be granted certification or license allowing the said organization to grow cannabis legally with the requirement that they have to keep up with terms of the new policy which was issued recently. This notification was given by the Drug Enforcement Administration (DEA). MedPharm Research is well-known as cannabis research and formulation development leader.
Albert Gutierrez, CEO of MedPharm, said:
“This is something we have been waiting for since we first sent in our application in September, 2016, as one of the first medical grow facilities to apply for a license,”
“Now, finally, the DEA has seen the importance of allowing federally legal grows to get more active in medical cannabis research, and do the work that we really need to do for patients across the country. It is a real game-changer for the whole medical cannabis industry.”
Stated on that letter given to Gutierrez, the Drug Enforcement Administration specified that MedPharm Research will receive a Notice of Proposed Rulemaking. As such, the company shall be requested to make comments regarding rules and regulations pertaining to growing cannabis as necessary for the purpose of medical research. But then again, timetable has yet to be set by the DEA depending on the completion of those regulations. Gutierrez said:
“We at MedPharm stand ready to assist the DEA in any way we can to help expedite this process, and bring to patients the best quality, FDA-approved cannabis that they need for research and treatment as quickly as possible,”
A contract was awarded to the Research Institute of Pharmaceutical Sciences at the University of Mississippi School of Pharmacy as reported in the University of Mississippi News in 1968. Stated in that contract is consenting the institute to grow cannabis as a product for research.
The said facility operated for more than 50 years as they are the only institution granted a license by the Drug Enforcement Administration to deliver permissible marijuana to facilities conducting medical research. Based on their study, they concluded that university-grown marijuana is of no use because of its poor quality. Thus, such product is not effective for the administration of research and lab work as well as testing for human use. The results are therefore not as reliable for medical research under the Food and Drug Administration.
Due to the rise of medical marijuana research, the DEA was pressured by an increasing number of medical marijuana researchers to provide other license and certification to other reliable facilities. Furthermore, the Drug Enforcement Administration said that licensing for companies who would like to grow legal cannabis will be open for application. This statement was circulated in August of 2016. As of June 2019, however, nothing was implemented ever since the application was enforced when the DEA was sued for irrational and unreasonable delays by one of the applicants. This fact is now prompting today’s immediate answer.
MedPharm is one among the primary suppliers of legal marijuana intended for research and is now in the right position to work with the Drug Enforcement Administration. Included in the application are formulating objectives for research and constructing venues appropriate for growing cannabis intended for medical research.
https://timesofcbd.com/dea-grants-medpharm-on...marijuana/
Sam'd'Mil' you may be very right. Doctor Dalton will be working this holiday weekend. So could the big reveal be next week? Perhaps just the start of a cascade of events that lead to the big reveal.
Aug 28, 2019, 02:53pm
The DEA Is Rewriting Obama's Federal Cannabis Regulations
https://www.forbes.com/sites/sarabrittanysomerset/2019/08/28/the-dea-has-rewritten-obamas-federal-cannabis-regulations/#2e0d9b493dae
RECENT DEA DECISIONS AND RULINGS
Increasing the Number of Authorized Marijuana Manufacturers Supplying Researchers -
DEA announced a policy change designed to foster research by expanding the number of DEA- registered marijuana manufacturers. This change should provide researchers with a more varied and robust supply of marijuana. At present, there is only one entity authorized to produce marijuana to supply researchers in the United States: the University of Mississippi, operating under a contract with NIDA. Consistent with the CSA and U.S. treaty obligations, DEA’s new policy will allow additional entities to apply to become registered with DEA so that they may grow and distribute marijuana for FDA-authorized research purposes.
This change illustrates DEA’s commitment to working together with the FDA and NIDA to facilitate research concerning marijuana and its components. DEA currently has 350 individuals registered to conduct research on marijuana and its components. Notably, DEA has approved every application for registration submitted by researchers seeking to use NIDA-supplied marijuana to conduct research that HHS determined to be scientifically meritorious.
Source: United States Drug Enforcement Administration
US firm launches cannabis supply chain certification
LeafWorks, a California-based plant genetics company specializing in botanical identification, launched its proprietary LeafWorks Supply Chain Certification recently to combat fraud and mislabeling in the marketplace and solve a pervasive problem faced by cannabis cultivators, distributors and consumers: verifiable ingredient authenticity and sourcing.
The certification offers guaranteed transparency across every step of the cannabis supply chain and helps businesses build brand equity and consumer confidence, said a company press release.
https://www.hempbenchmarks.com/supply-chain.html
States Can’t Block Legal Hemp Shipments within Their Borders, USDA Says
The U.S. Department of Agriculture (USDA) said on Tuesday that hemp can be transported across state lines—even through states that haven’t enacted laws allowing the crop’s production—and that the descheduling of the plant and its derivatives under the 2018 Farm Bill are already in effect because they are self-executing and do not require further action by federal agencies.
https://www.hempbenchmarks.com/supply-chain.html
USDA Clarifies that Farmers can Import Hemp Seeds from Other Countries
The U.S. Department of Agriculture (USDA) clarified on Friday that hemp seeds can be imported into the U.S., and that the Justice Department no longer has a role in that process.
While USDA is still developing regulations for hemp cultivation under the 2018 Farm Bill, which federally legalized the crop and its derivatives, farmers can still obtain seeds in the meantime.
The agriculture legislation “removed hemp and hemp seeds from DEA authority for products containing THC levels not greater than 0.3 percent” and “DEA no longer has authority to require hemp seed permits for import purposes.”
https://www.hempbenchmarks.com/supply-chain.html
Kgem
Just a few thoughts for all to consider on a humid summer day. Today, few industries are booming as big as the extraction industry is right now. And, whether it is cannabis or hemp, high-quality end products are in high demand and in short supply. Everyday consumers are becoming savvier like never before, closely scrutinizing the products they buy from this industry. Often, the labels are confusing, and the dose is difficult to ascertain even when clearly stated. For example, if the label tells one to take half an eye dropper of CBD oil, but the pipet on the dropper is not calibrated, then how much are you taking? Does half an eyedropper mean from the tip to half way, or does it mean something else.
High-quality end products require high-quality methods of production and processing. Large yields of high-quality products require innovation and technology in order to scale for increased consumer demand --- all while keeping production costs at a minimum. Honesty, integrity, and trustworthiness are the coins of the realm in this environment, and the best companies strive to meet all these criteria. But without FDA approval, what can a company do? In Doctor Dalton’s case (UNVC), he sought CARF approval which is the next best thing to FDA approval. Other methods include Kosher Certification, and still others attempt to develop industry standards. In the end, the very best cannabis companies are likely to embrace all of these standards.
In the rush to succeed in this industry, it's also easy to overlook the increasing impact that GMP (Good Manufacturing Process) compliance will have on consumer products. Not all extraction methods bode well for GMP compliance, as many big companies are now finding out. Perhaps this is what Doctor Dalton (UNVC) truly means when is says the last will finish first. I suspect we are all soon to find out.
Kgem
Everyone should carefully read the following --- this directly impacts all who invest in cannabis companies.
Credit Unions Can Bank Hemp Businesses, Federal Agency Announces
Published 6 hours ago on
August 19, 2019
By
Kyle Jaeger
A federal financial agency released updated guidelines on banking in the hemp industry on Monday, following up on requests from multiple lawmakers to provide clarity on the issue.
The National Credit Union Administration (NCUA) said in its interim guidance that providing banking services to hemp businesses is allowable since the crop and its derivatives were federally legalized under the 2018 Farm Bill. The notice also emphasized the economic potential of hemp and the role credit unions can play as the industry continues to develop.
“Lawful hemp businesses provide exciting new opportunities for rural communities,” NCUA Chairman Rodney Hood said in a press release. “I believe today’s interim guidance keeps with the mission of the nation’s cooperative credit system to serve people who have been overlooked and underserved.”
“Many credit unions have a long and successful history of providing services to the agriculture sector,” he said. “My expectation is that credit unions will thoughtfully consider whether they are able to safely and properly serve lawfully operating hemp-related businesses within their fields of membership.”
In a letter sent to Sen. Michael Bennet (D-CO) last month, which the presidential candidate’s Senate office shared exclusively with Marijuana Moment, Hood noted that NCUA was “working on possible future guidance to financial institutions” but that such guidance would be subject to change depending on what regulations the U.S. Department of Agriculture (USDA) ultimately develops.
In the meantime, the new interim guidance notes that “growth in hemp-related commerce could provide new economic opportunities for some communities, and will create a need for such businesses to be able to access capital and financial services” while clarifying that credit unions “may provide the customary range of financial services for business accounts, including loans, to lawfully operating hemp related businesses within their fields of membership.”
While NCUA said that it is “generally a credit union’s business decision as to the types of permissible services and accounts to offer,” it highlighted the need to comply with the Bank Secrecy Act (BSA) and with Anti-Money Laundering (AML) requirements, in particular:
—Credit unions need to maintain appropriate due diligence procedures for hemp-related accounts and comply with BSA and AML requirements to file Suspicious Activity Reports (SARs) for any activity that appears to involve potential money laundering or illegal or suspicious activity. It is the NCUA’s understanding that SARs are not required to be filed for the activity of hemp-related businesses operating lawfully, provided the activity is not unusual for that business. Credit unions need to remain alert to any indication an account owner is involved in illicit activity or engaging in activity that is unusual for the business.
—If a credit union serves hemp-related businesses lawfully operating under the 2014 Farm Bill pilot provisions, it is essential the credit union knows the state’s laws, regulations, and agreements under which each member that is a hemp-related business operates. For example, a credit union needs to know how to verify the member is part of the pilot program. Credit unions also need to know how to adapt their ongoing due diligence and reporting approaches to any risks specific to participants in the pilot program.
—When deciding whether to serve hemp-related businesses that may already be able to operate lawfully–those not dependent on the forthcoming USDA regulations and guidelines for hemp production–the credit union needs to first be familiar with any other federal and state laws and regulations that prohibit, restrict, or otherwise govern these businesses and their activity. For example, a credit union needs to know if the business and the product(s) is lawful under federal and state law, and any relevant restrictions or requirements under which the business must operate.
“Hemp provides new opportunities for communities with an economic base involving agriculture,” the notice states. “The NCUA encourages credit unions to thoughtfully consider whether they are able to safely and properly serve lawfully operating hemp-related businesses within their fields of membership.”
“Lending to a lawfully operating hemp-related business is permissible.”
After USDA releases its rules for the hemp industry, which are expected to come ahead of the 2020 planting season, NCUA said it “will issue additional guidance on this subject.”
Senate Majority Leader Mitch McConnell, who like Bennet has also pressured federal regulators to clear up confusion around hemp banking, took credit for NCUA’s response and celebrated the new guidance.
“I’m delighted to hear the NCUA has answered my call on behalf of Kentuckians to ensure the legal hemp industry can access much-needed financial services,” McConnell said in a press release. “Although President Trump signed into law my initiative last year to remove hemp from the federal list of controlled substances, many of my constituents have told me about their difficulty receiving loans and other services that are necessary to successfully run a hemp business.”
“Through this guidance by the NCUA, I look forward to more hemp farmers, processors and manufacturers starting or growing their operations with the help of Kentucky’s credit unions,” he said. “As Senate Majority Leader, I’ll continue advocating for Kentucky’s priorities throughout the federal government, and I’m proud of today’s positive news.”
Credit unions have generally been friendlier to the marijuana and hemp industries than have conventional banks, and NCUA has similarly taken a more proactive role in evolving to meet the demands of these burgeoning markets.
For example, the agency’s head clarified earlier this month that credit unions wouldn’t be punished simply for serving hemp businesses so long as they were following standard procedures. NCUA also released a draft rule in July that would allow people with past drug convictions to work at credit unions.
Cannabis banking issues have received significant congressional attention this session, with a bipartisan consensus emerging around creating a legislative fix so that hemp and marijuana businesses are able to access financial services.
The hemp industry in particular has enjoyed bipartisan support since the crop was legalized, but while marijuana remains a federally controlled substance, more lawmakers from across the aisle are expressing interest in affording cannabis businesses the same access in order to increase financial transparency and mitigate public safety risks associated with operating on a largely cash-only basis.
The House Financial Services Committee approved a bill in March that would protect banks that service marijuana businesses from being penalized by federal regulators, and the Senate Banking Committee also held a hearing on the issue last month.
Banking Chairman Mike Crapo (I-ID), who suggested earlier this year that his panel wouldn’t convene to discuss the matter as long as cannabis is federally illegal, has since taken a stance that the issue needs to be resolved.
But while advocates hoped that legislation to address marijuana banking problems would be taken up by the full House ahead of the August recess, that window closed and attention is now turned to a potential hearing in the fall.
https://www.marijuanamoment.net/credit-unions-can-bank-hemp-businesses-federal-agency-announces/
Could a cannabis substance replace opioid pain relievers?
By Lauren Sharkey - Published Today
Researchers have known about the pain relieving potential of cannabis for decades, but they have had to wait until now to determine how the plant creates such effective substances. Their findings may help provide a solution to the opioid crisis.
People can treat chronic pain using a number of different medications. However, doctors commonly prescribe opioids for pain that is constant.
Opioids work by attaching themselves to nerve cell receptors in various parts of the body, blocking pain signals that are traveling to the brain.
Although effective, the downside of opioids is the risk of addiction — especially when a person takes them for an extended period.
More than 130 people in the United States die of an opioid overdose each day, according to the National Institute on Drug Abuse. The problem is so severe that officials have labeled it as a public health crisis.
"There's clearly a need to develop alternatives for relief of acute and chronic pain that go beyond opioids," says Prof. Tariq Akhtar, from the department of molecular and cellular biology at the University of Guelph in Ontario, Canada.
According to Prof. Akhtar and other researchers at the university, cannabis could be the key.
Ideal pain relievers
In the 1980s, scientists identified two cannabis molecules: cannflavin A and cannflavin B. "These molecules are nonpsychoactive, and they target the inflammation at the source, making them ideal painkillers," explains Prof. Akhtar.
In fact, research found that flavonoids, as the molecules are now known, are almost 30 times better at reducing inflammation than aspirin.
But, due to regulatory laws, researchers made little progress in figuring out how the cannabis plant makes flavonoids. Until now, that is.
Cannabis use has now become normalized and even legal in some places, including Canada. The University of Guelph team used this change of situation to delve into the molecule-making process.
"Our objective was to better understand how these molecules are made, which is a relatively straightforward exercise these days," says Prof. Akhtar.
"There are many sequenced genomes that are publicly available, including the genome of Cannabis sativa, which can be mined for information. If you know what you're looking for, one can bring genes to life, so to speak, and piece together how molecules like cannflavins A and B are assembled."
Creating bigger batches
Using biochemistry methods, the team was able to determine the plant genes necessary to produce the two molecules.
They also identified the precise steps that resulted in flavonoid production, publishing them in Phytochemistry.
However, this research alone is not enough to create a new natural pain reliever. "The problem with these molecules is they are present in cannabis at such low levels, it's not feasible to try to engineer the cannabis plant to create more of these substances," states Prof. Steven Rothstein, also from the molecular and cellular biology department.
Consequently, the researchers are teaming up with cannabis company Anahit International Corp. in the hope of finding a way to "engineer large quantities" of flavonoids.
"Anahit looks forward to working closely with University of Guelph researchers to develop effective and safe anti-inflammatory medicines from cannabis phytochemicals that would provide an alternative to nonsteroidal anti-inflammatory drugs," says Anahit's chief operating officer Darren Carrigan.
Eventually, the company plan to make this remedy available via a range of athletic and medical products, including sports drinks, pills, creams, and transdermal patches.
In itself, this will be an achievement. But, if the partnership is successful, the best part is that the pain relief will come without an addiction risk.
"Being able to offer a new pain relief option is exciting, and we are proud that our work has the potential to become a new tool in the pain relief arsenal."
Prof. Steven Rothstein
https://www.medicalnewstoday.com/articles/325...b3ce9f3d94
New Article Hot Off The Press From Doctor Eric I. Mitchell
Be Careful What You Ask for:
You May Not Get It…..SEO
Hemp Oil, Hemp Seed Oil, Hemp Extract are not Hemp CBD oil, CBD oil, or CBD oil from Hemp. Was that confusing, and yes, it is. Yes, we live in a high-tech society but we still have to stop at red lights or risk being T-Boned. These red, yellow and green lights give us certain liberties to be safe if we obey them.
Beware! Artificial Intelligence (AI) is here! We hit the search button on our computers or ask Siri or Alexa to make your request, presto, you think you have the information for which you just asked or searched for. Not always true. Your words or typed phrases can be manipulated in this digital world by something called SEO, Search Engine Optimization. In searching for the right Cannabinoid, THC, CBD or CBC, “Be Careful What You Ask for”.
So, the light does not change within your reasonable allocated time for a red light. That does not mean that red light is stuck or broken, it is just taking too long and then we get T-boned. I am talking about a standard that does not exist, called common sense, that is what Ben Franklin said not me. We violate this little rule all the time because of our human nature and our quest of I want it now!
Talking about high-tech, we depend on these technological devices and sometimes that red light gets long. We can get locked-in so fast on what little information we do have in our search for new information. I started this blog warning that the SEO will give you selections you did not ask for because someone has used the SEO system and holds a higher ranking than other websites. Beware!
I am writing because I want you to know “what to ask for” because it is still the Wild, Wild West in the cannabis world. And a lot of this “shoot um-up” is because people just do not know what to ask for in their quest for this new yet very old botanical medicine called CBD. The American public is on a CBD craze about something they do not know much about but do not want to miss it. Hoorah, because I was curious, I have learned a lot about the Endocannabinoid System (ECS) and the effect of the cannabinoids on that system. I am here now to share what I have learned as a long-term practicing physician.
I cannot teach it all here in this blog but you have a green light to go to www.Hempci.com and under the research tab, read about our ECS and Vitamin CBD™ and the effects of Vitamin CBD™ on your body’s biological system.
Be careful what you ask for! Look for that blinking yellow light!
Written by
Eric I. Mitchell, MD FACPE
Doctor Eric I. Mitchell MD FACPE (this was just sent out today)
HAVE YOU HAD YOUR VITAMIN CBD™ TODAY?
IS IT REAL OR SNAKE OIL?
Research on the health effects of cannabis use in light of its increased medical uses and the current array of medical disorders needs more research. Our objective at Hemp Commodity Industries, LLC (HCI) is to explore the relationship between cannabis use and different results obtained with the use of Hemp-derived CBD oil which we have named Vitamin CBD™.
Current cannabis use is associated with lower odds of metabolic syndrome across emerging and middle-aged US adults. Future studies by HCI will be to examine the biological pathways of this relationship. There are many other diseases or maladies which also claimed great benefits with the use of Vitamin CBD™. These claims have both a positive and negative effect on the value of this age-old botanical. The positive is that results speak for themselves, however, because of the cross section of different maladies which are reporting positive outcomes, people want to call it snake oil. But be careful, there is a lot of science behind the Endocannabinoid System (ECS) which has not been taught to our healthcare providers mainly because of its illegality imposed on Cannabis sativa L in 1970 by then President Nixon who made Cannabis sativa L a Federal crime.
The ECS was discovered in Israel by Dr. Ralphal Mechoulam in 1992 and at the time of this writing, allopathic medical schools were still not teaching this existence of this biological regulatory system, which have many different endpoints in the anterograde and retrograde synaptic neurotransmitter.
The need for clinical data always follows the introduction of a new science that is not so new. However, a new attitude is prevailing and researchers are jumping at this new window of opportunity for research without the oversight and cloud of the DEA.
There is little understanding on which Terpenes, Cannabinoids, or phytocannabinoids are responsible for these clinical outcomes in full. HCI will undertake this research project with production of known ratios of THCV to THC and the Terpenes types with their effect on the Cannabinoids. The hypothesis and antidotal impression gleaned from early data must be moved to theory based on and must have clinical application to test our outcomes.
Common practice use of any agent is supported by strong clinical results. HCI’s micropropagation technology allows for thousands of copies of a single plant to be produced in a short amount of time with the desired amount of THCs, CBDs and in our research mode with Terpenes. The singular genetic profile of plants high in a given Terpene, i.e. pinene can be produced from micropropagation which allows these plants to establish more quickly, grow more vigorously, and have a more uniform production cycle than a heterogeneous population. This will give HCI the strategic ability to supply our research projects with a sample profile which is known and can be dispensed in the non-flower form chosen for the research protocol directed toward the reduction of pathology and symptoms of known maladies.
The growth of cannabis plants selected from Micropropagation consists of five stages as outlined above: 1) source plant preparation; 2) culture initiation; 3) multiplication; 4) pre-transplant/rooting; 5) transplant/acclimatization. Technicians will remove a sample of tissue from the source plant, sterilize the tissue sample and place it onto a nutrient medium, Petri dish just like in general chemistry, containing growth regulators to begin the dedifferentiation process and proliferation of plant cells.
HCI uses natural lighting for most of its daily light needs because it is the best choice: natural sunlight provides the correct quality and quantity of light for plant production. Sunlight also increases terpene production, increases cannabinoid concentrations, and reduces the potential for plant disease.
This brings us back to Vitamin CBD™ and some of the maladies which have been helped with HCI’s growing, harvesting and processing this hemp-derived CBD oil. Here at HCI, we know every step in the process because HCI has done every step in this process. The chain of custody has been totally within our purview which gives the best command and control over our products.
When you white label a product, you are depending on another source for your most essential part of your equation without a knowledge base. HCI products are not white labels products!
“Have you had your Vitamin CBD™ today for your mental clarity and your bone health”. This is HCI’s promotional byline but CBD will do more than the two illustrated reasons above to take this vitamin to enhance the overall performance of the ECS.
The list is growing for uses of CBD, but what you must remember is that our ECS works within our neurotransmission system and can have many different effects for different maladies and it’s not snake oil.
Written by: Eric I. Mitchell MD FACPE
www.vitamincbd.life
Abazaba, I know you have been around a long time, and typically do not need someone to tell you when to buy UNVC or any stock for that matter. If you don't have a "good reason" to buy UNVC, then that is okay by me. It is my understanding the market works best when some people buy while others are uncertain or have a desire to sell. UNVC is a good buy because this price is cheap (recently, it has been much higher).
I buy CBD products from a competitor while waiting for Dalton to get his product to market. Yesterday that competitor (who knows Dalton very well) told me Dalton and Univec are the real deal, and that this will be big. Mind you, this was told to me by a competitor in the CBD business who knows I own Univec shares and buy his products while waiting for Dalton's products to become available. There simply is no good reason for this guy to tell me this.
Bottom line, if you are uncertain, and not buying, then that makes it easier for me to pick up cheap shares. Thank you. Feel free to tell all your strategy going forward.
I looks like Doctor Dalton is about to put the hammer down. UNVC will run like no other. So much wealth creation, and so little time. Will the world ever be the same? I say no. Doctor Dalton is soon to change the world.
Great info showing a dramatic increase in HRI revenue numbers --- good job all. To say Doctor Dalton does not do things the way most others do is such an understatement. This just keeps getting better all the time.
Normally, I would not suggest news during a holiday week, or even during the entire month of July for that matter. The fact is, most penny stock investors take the summer off and are simply not around. However, Dalton is not your typical CEO, and that means nothing can be ruled out. This week we see an enhanced twitter opening page with improved graphics and a lot more posting. Those posts seem to indicate something is brewing, and whatever it is, it looks to be big.
Perhaps Dalton knows the video and interview from IFAH will soon be out. If so, then let me suggest that what is presented will involve Univec. You see, Doctor Dalton contacted me before the IFAH conference and asked that I explain to long term investors the importance of IFAH for Univec investors. At that time, Hope Global had not yet taken place, and instead of mentioning Hope Global, he talked about IFAH. IFAH was about what Doctor Dalton had already accomplished (not what he hopes he may be able to accomplish sometime in the distant future), and the award Dalton received designated him as one of the top 100 healthcare professionals in the ENTIRE world.
If not about IFAH, then what may soon develop? How about new medications fresh out of clinical trials or new OTC products to improve nearly everything. One of the biggest money making products sold by big pharma is blood pressure medications. Studies indicate CBD oil can reduce blood pressure in seniors and without the massive side effects commonly found with most blood pressure medications. How about sleep aids? Did you know CBD can improve your sleep experience and result in a more restful and refreshed night sleep? How about anxiety? CBD reduces anxiety and can improve your daily experience. The list just goes on and on.
The world is changing folks, and Doctor Dalton and Univec will soon lead the way.
Kgem
Vinsterr, wouldn't that be nice. What we can say for certain is
this mention of a PR is new and certainly may be a hint of what may be coming. In my opinion, a whole series of 8ks will likely start flowing once the gates are finally open. How big will this conglomerate be and what might be the scope of our operations? The answer to those questions might very well blow people away as well. Attempts to estimate revenues for such a conglomerate are just as mind blowing. Think about major CBD treatments adopted by big pharma and throw in dozens of OTC products as well. Even putting these pieces to the puzzle together still does not encompass the true extent of our operations --- we still have the V.A. and a host of cosmetics and CARF approved clinics and 70,000 pharmacies and we aren't even talking about hemp fiber and all those uses. A conglomerate can operate in multiple directions, and thinking only about medical may be thinking far too small.
Dr. David Dalton? @DrDavidDalton1
Naysayers, Flippers, Marketmakers steal wealth by fear impatience and deceit. Everyday trying to create panic. The float will dry up. PR will make new beginnings. Univec Conglomerate Inc. Book it.
https://twitter.com/DrDavidDalton1
Univec Conglomerate Inc.
Is for all “people” to create wealth and change the world. Everyone makes money, Even naysayers and flippers that use fear to gain a few pennies, know their game. Success is in my DNA, I will not fail nor can I Control process but I can complete the goals
Everyday another goal completed and a process done. Everyday we help those less fortunate and are in need of help both physically and mentally. We all will get there together. BOOK IT
https://www.linkedin.com/in/david-dalton-58008952
Univec Conglomerate Inc. Through our subsidiary PPSI will see our Veterans have access to CBD and Medical Marijuana. Always part of the plan. Congress didn’t do it. We will make the change. Connect the dot. Yes I am a Veteran. BOOK IT.
Univec Conglomerate Inc. Through our subsidiary PPSI will see our Veterans have access to CBD and Medical Marajuana . Always been part of our plan. Congress didn’t do it. We will make the change. Connect the dot. Yes I am a Veteran. Book it
— Dr. David Dalton (@DrDavidDalton1) June 22, 2019